Arch Biopartners Inc.
ARCH.V
Toronto Stock Exchange Ventures0.79
CAD
-0.13
- -
Arch Biopartners Inc.
ARCH.V
(Toronto Stock Exchange Ventures)
Recent
price
0.79
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arch Biopartners Inc is a therapeutic biotechnology company specializing in the development of novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The company's core product portfolio includes LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II clinical trials aimed at preventing cardiac surgery-associated AKI; cilastatin, a repurposed drug also in Phase II targeting toxin-induced kidney damage prevention; and a pre-clinical chronic kidney disease platform focusing on interleukin-32 (IL-32) inhibition. These products represent distinct, mechanism-based therapeutic approaches addressing inflammation and toxin-induced kidney injury, two critical unmet medical needs affecting millions globally. Arch operates primarily out of its headquarters in Toronto, Canada, and targets the pharmaceutical and healthcare sectors with a focus on kidney disease therapeutics. In the last two years, Arch Biopartners has strategically expanded its pipeline and capabilities through significant developments. In September 2025, the company acquired a novel CKD platform via the acquisition of Lipdro Therapeutics Inc., which enhances its pre-clinical IL-32 cytokine inhibition platform with potential to advance next-generation CKD drug candidates. Additionally, Arch has expanded the scope of its Phase II cardiac surgery-associated AKI trial to include new clinical sites such as Toronto General Hospital, reflecting a scale-up in its clinical development efforts. This acquisition and trial expansion mark a major strategic effort to consolidate its position as a leading developer of kidney therapeutics. Arch also entered into a worldwide license agreement to repurpose cilastatin for AKI treatment, reinforcing its commitment to addressing acute and chronic kidney conditions through innovative drug candidates. Founded in 2003, Arch Biopartners serves the global biotech and pharmaceutical industries, focusing on developing treatments for severe kidney injuries and diseases. Its products and clinical programs are specifically aimed at medical institutions, research centers, and pharmaceutical partners worldwide. The company leverages its scientific expertise in kidney disease pathology and drug development to create therapeutic solutions addressing immune-mediated and toxin-mediated mechanisms of kidney injury. Arch Biopartners remains one of the niche biopharma companies with a specialized focus on kidney disease, advancing clinical assets through focused R&D and strategic acquisitions in Canada and internationally.